Public-domain · open source
OpenJurist
← 254 F.3d 1031 - Apotex USA, Inc. v. Merck & Co.

Apotex USA, Inc. v. Merck & Co.’s Empirical Analysis

254 F.3d 1031 · 2001

Citation profile

70
cited by 70 later decisions
August 2015
most recently cited

12 federal appellate · 22 district ·

Relationships

Relies on Anderson v. Liberty Lobby, Inc. · American Hoist Derrick Company v. Sowa & Sons Inc · Hybritech Inc. v. Monoclonal Antibodies, Inc. · Ethicon Endo-Surgery, Inc. v. United States Surgical Corp. · Price v. Symsek

Most-quoted passages

The sentences later courts lift from this opinion, ranked by how many decisions quote each — the parts of the opinion doing the work. These counts are smaller than the citation total above because most of the 70 citing decisions cite the case generally; a passage count includes only decisions quoting that exact language verbatim.

  1. “[T]he spirit and policy of the patent laws encourage an inventor to take steps to ensure that "the public has gained knowledge of the invention which will insure its preservation in the public domain” or else run the risk of being dominated by the patent of another. Palmer v. Dudzik, 481 F.2d 1377 , 1387 (C.C.P.A.1973).... Absent a satisfactory explanation for the delay or the presence of other mitigating facts, a prior invention will therefore be deemed suppressed or concealed within the meaning of § 102(g) "if, within a reasonable time after completion, no steps are taken to make the invention publicly known.” [Int'l Glass Co., Inc. v. United States, 408 F.2d 395 , 403 (Ct.Cl. 1969)].”
    1 later decision quote this exact passage · from the majority
  2. “In 1991, Merck and its Canadian subsidiary, Merck Frosst Canada, Inc., sued Apotex’s Canadian affiliate, Apotex Canada, for infringement of Merck’s Canadian patent covering the enalapril sodium compound. [.Apotex /] at . During the 1994 trial (“the Canadian trial”), Brian McLeod, Merck’s then-vice president of marketing, performed a step-by-step narration of a videotape demonstrating Merck’s process of manufacturing VA-SOTEC(R). Id. Within days of hearing this testimony, Dr. Bernard Sherman, an Apotex official, allegedly conceived the patented process at issue. Id.”
    1 later decision quote this exact passage · from the majority
  3. “the invention was made in this country by another inventor,” 35 U.S.C. § 102 (g), the burden of production shifts to the patentee to produce evidence sufficient to create a genuine issue of material fact as to whether the prior inventor has suppressed or concealed the invention, although the ultimate burden of persuasion remains with the party challenging the validity of the patent. See id. at 1037-38 . An anticipation/obviousness defense such as that asserted by BD/Nova here is distinct from a”
    1 later decision quote this exact passage · from the majority

How this case has been treated — in progress

Whether each later court followed, distinguished, criticized, or overruled this decision. The treatment classification (task #35) runs highest-cited cases first and lights up here as it reaches this one.